Tag: Immunotherapy
Analyst Ratings Update: Adaptimmune Therapeutics (NASDAQ: ADAP)
Adaptimmune Therapeutics, a clinical-stage biopharmaceutical company, has recently garnered the attention of analysts, with a mix of bullish and bearish sentiments. In the past...
Limited Benefit of Nivolumab/Tivozanib in Advanced RCC Post-Immunotherapy
The combination of nivolumab and tivozanib did not show an improvement in progression-free survival (PFS) for patients with advanced metastatic renal cell carcinoma (RCC)...